• September 1 (THU)
  • September 2 (FRI)

Sep. 1 (Thu)

ASCO/KSMO Joint Symposium 1

Application of precision medicine in rare cancers: Approaching genetic landscape into rare cancers
Date & Time Sep. 1 (Thu), 09:00-10:15 Venue Room A
Chairs
  • Joong Bae Ahn (Yonsei Cancer Center, Korea)
  • Everett Vokes (University of Chicago Medicine (American Society of Clinical Oncology), USA)
Presentation
Detail
  1. 1.Rare cancers in the multi-omic era
    Razelle Kurzrock (Medical College of Wisconsin, USA)
  2. 2.Basket trial for rare cancers and tissue agnostic approach
    Bhumsuk Keam (Seoul National University Hospital, Korea)
  3. 3.Challenges in adaptation of precision medicine to rare cancers
    Andrea Necchi (Vita-Salute San Raffaele University, Italy)

Scientific Symposium 1

Tissue-agnostic therapeutics
Advances in precision medicine in oncology have provided the research on targeted therapies across different tumor types, regardless of their site of origin, a concept known as a tissue-agnostic indication. These therapeutics are based on molecular characteristics rather than tumor location or tissue type. As our understanding of the molecular characteristics of tumors has improved, there has been a tremendous leap forward in developing targeted and tissue-agnostic therapies. This session will discuss the future perspectives on immune checkpoint inhibitors, TRK inhibitors, and KRAS inhibitors and a novel framework of clinical trials to support the tumor-agnostic approach.
Date & Time Sep. 1 (Thu), 09:00-10:30 Venue Room B
Chairs
  • Dong-Wan Kim (Seoul National University Hospital, Korea)
  • Dung T. Le (Johns Hopkins University School of Medicine, USA)
Presentation
Detail
  1. 1.Immunotherapy as a tissue-agnostic drug: From discovery to future perspectives
    Dung T. Le (Johns Hopkins University School of Medicine, USA)
  2. 2.KRAS inhibitor as a tissue-agnostic drug?: From discovery to future perspectives
    David S. Hong (MD Anderson Cancer Center, USA)
  3. 3.Evolution of precision paradigm: Novel framework of clinical trial to support tumor-agonistic approach
    Vivek Subbiah (MD Anderson Cancer Center, USA)
  4. 4.Tumor-agnostic TRK inhibitor therapy for NTRK fusion-positive cancers
    Alexander Drilon (Memorial Sloan Kettering Cancer Center, USA)

Scientific Symposium 2

Proteomics & epigenomics – Updates, clinical application, clinical trial
Proteomics and epigenomics results are being actively used to classify subtypes of cancer and discover biomarkers for prediction and prognosis. Recently FDA-approved tests with clinical utility came from the study result under CPTAC (Clinical Proteomic Tumor Analysis Consortium) in the United States. In this session, we would like to share the vision of prominent researchers with the latest research results in this proteomics and epigenomics field.
Date & Time Sep. 1 (Thu), 09:00-10:30 Venue Room C
Chairs
  • Jong Bae Park (National Cancer Center Graduate School of Cancer Science and Policy, Korea)
  • Yu-Ju Chen (Academia Sinica, Taiwan)
Presentation
Detail
  1. 1.Opportunity for proteomics-guided precision oncology
    Yu-Ju Chen (Academia Sinica, Taiwan)
  2. 2.Proteogenomics aspects in glioblastoma evolution by standard treatment
    Jong Bae Park (National Cancer Center Graduate School of Cancer Science and Policy, Korea)
  3. 3.Proteogenomic analysis of human cancers
    Daehee Hwang (Seoul National University, Korea)
  4. 4.Genome-wide methylation analysis of cancers and application to early cancer diagnostics
    Duhee Bang (Yonsei University, Korea)

Satellite Symposium 1
ASCO

New era of NSCLC EGFR mutation treatment_Updated overall survival analysis: 3G EGFR TKI Lazertinib
Date & Time Sep. 1 (Thu), 9:00-9:40 Venue Room D
Chair
  • Myung-Ju Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. Lazertinib, a new game-changer in EGFR-mutant NSCLC
    Ji-Youn Han (National Cancer Center, Korea)

Satellite Symposium 2
ASCO

Efficacy and safety of Gavreto for RET+ patients
Date & Time Sep. 1 (Thu), 9:50-10:30 Venue Room D
Chair
  • Byoung Yong Shim (The Catholic University of Korea St. Vincent’s Hospital, Korea)
Presentation
Detail
  1. The welcome rain, Gavreto: New hope for RET+ patients
    Dae Ho Lee (Asan Medical Center, Korea)

Plenary Lecture 1

Drug screening and oncology drug discovery
Todd Golub is a world-renowned physician-scientist who pioneered the application of genomics to cancer biology and therapeutic discovery. Throughout his career, Golub has advocated for the free, rapid sharing of large-scale genomic data and tools to accelerate the pace of biomedicine, and is deeply committed to patient-focused research. He is Director of the Broad Institute of MIT and Harvard, and also a member of the faculty of the Dana-Farber Cancer Institute and Harvard Medical School.
Date & Time Sep. 1 (Thu), 10:50-11:30 Venue Room A
Chair
  • Young Suk Park (Samsung Medical Center, Korea)
Presentation
Detail
  1. 1.Drug screening and oncology drug discovery
    Todd Golub (Broad Institute and Dana-Farber Cancer Institute, USA)

Luncheon Symposium 1

Present and future insight for the management of unresectable colorectal cancer
Date & Time Sep. 1 (Thu), 11:30-12:10 Venue Room A,B
Chair
  • Jong Gwang Kim (Kyungpook National University Chilgok Hospital, Korea)
Presentation
Detail
  1. 1.Colorectal cancer treatment: What is my choice?
    Jwa Hoon Kim (Korea University Anam Hospital, Korea)
  2. 2.Colorectal cancer treatment: Future perspectives & strategies
    Sun Young Kim (Asan Medical Center, Korea)

Luncheon Symposium 2

Raise the awareness about expanded new indication (KEYNOTE-522) of high risk early TNBC for KEYTRUDA and deliver the value of KEYTRUDA in the treatment of TNBC patients suffering from cancer and emphasizing the importance of early treatment
Date & Time Sep. 1 (Thu), 11:30-12:10 Venue Room C,D
Chair
  • Kyong Hwa Park (Korea University Anam Hospital, Korea)
Presentation
Detail
  1. 1.Pembrolizumab: Transforming the treatment journey for TNBC
    Min Hwan Kim (Yonsei Cancer Center, Korea)

Scientific Symposium 3

Up to date knowledge of GU cancer
The genitourinary cancer session is composed of up-to-date results of the latest research in the fields of prostate cancer, RCC, and urothelial carcinoma. In this session, contents that can be applied to real practice, along with the latest knowledge on genitourinary cancer, have been prepared. First, recent advances in prostate cancer and kidney cancer will be discussed. Second, treatment strategy including maintenance therapy of ICI and efficacies of FGFR signaling targeted therapy as an important target molecule in urothelial carcinoma, will be presented.
Date & Time Sep. 1 (Thu), 12:40-14:10 Venue Room A
Chairs
  • Sun Young Rha (Yonsei Cancer Center, Korea)
  • Ignacio Duran (Hospital Universitario Marques de Valdecilla-Idival Santander, Spain)
Presentation
Detail
  1. 1.New agents and advances into current prostate cancer treatment
    Himisha Beltran (Dana Farber Cancer Institute, Harvard Medical School, USA)
  2. 2.Treatment approaches with immunotherapy and targeted agents in RCC
    Woo Kyun Bae (Chonnam National University Hwasun Hospital, Korea)
  3. 3.Transforming treatment of advanced urothelial carcinoma
    Minsuk Kwon (Ajou University Hospital, Korea)
  4. 4.Gain special insights on targeting FGFR signaling in bladder cancer
    Ignacio Duran (Hospital Universitario Marques de Valdecilla-Idival Santander, Spain)

Scientific Symposium 4

Big data & AI: Cancer genome & diagnosis
Artificial intelligence (AI) and machine learning have significantly influenced cancer diagnosis and treatment more and more since the introduction of next generation sequencing (NGS). It is imperative to detect novel biomarkers that induce drug resistance and identify therapeutic targets to enhance the efficacies of treatment. NGS generates large datasets that demand specialized bioinformatics resources to analyze the data which are relevant and clinically significant. Therefore, there is still a big hurdle to interpret and use it in daily practice for clinicians. In this session, experts in this field will show the current status of implementing AI in precision oncology and share their perspectives.
Date & Time Sep. 1 (Thu), 12:40-14:10 Venue Room B
Chairs
  • Keun-Wook Lee (Seoul National University College of Medicine / Seoul National University Bundang Hospital)
  • Peter Park (Harvard Medical School, USA)
Presentation
Detail
  1. 1.Large-scale single-cell-based deconvolution of pan-liver diseases and spatial transcriptomics identified a novel cell-based marker in liver cancer
    Bin Chen (Michigan State University, USA)
  2. 2.Identification of patients with homologous recombination deficiency from sequencing data
    Peter Park (Harvard Medical School, USA)
  3. 3.Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes correlated with distinct genomic profiles and clinical outcomes of immune checkpoint inhibitors
    Chan-Young Ock (Lunit Inc., Korea)
  4. 4.Computing cancer immunity for informing precision oncology
    Zlatko Trajanoski (Medical University of Innsbruck, Austria)

Satellite Symposium 3
ASCO

What is the roles of Lonsurf (FTD/TPI) for the treatment of CRC/GC patients?
Date & Time Sep. 1 (Thu), 12:40-13:20 Venue Room C
Chair
  • Hei-Cheul Jeung (Gangnam Severance Hospital, Korea)
Presentation
Detail
  1. 1.The role of FTD/TPI in treatment of patients with mCRC
    Ji Hyung Hong (The Catholic University of Korea Eunpyeong St. Mary's Hospital, Korea)
  2. 2.The role of FTD/TPI in treatment of patients with mGC
    Hyung-Don Kim (Asan Medical Center, Korea)

Satellite Symposium 4
ASCO

Delving deeper into the 1st & 2nd line setting CDK4/6 inhibitor data (abemaciclib) for patients with HR+ HER2- metastatic breast cancer
Date & Time Sep. 1 (Thu), 12:40-13:20 Venue Room D
Chair
  • Sung-Bae Kim (Asan Medical Center, Korea)
Presentation
Detail
  1. Delving deeper into the 1st & 2nd line setting CDK4/6 inhibitor data (abemaciclib) for patients with HR+ HER2- metastatic breast cancer
    Antonio Llombart (Hospital Arnau Vilanova, Spain)

Satellite Symposium 5
ASCO

Treatment strategy for uHCC patients: What can we expect from TKIs in uHCC treatment?
Date & Time Sep. 1 (Thu), 13:30-14:10 Venue Room C
Chair
  • Baek-Yeol Ryoo (Asan Medical Center, Korea)
Presentation
Detail
  1. 1.The current role of Lenvatinib in Japanese clinical practice
    Masayuki Kurosaki (Musashino Red Cross Hospital, Japan)
  2. 2.What can we expect from TKIs in uHCC treatment?
    Jaekyung Cheon (Cha Bundang Medical Center, Korea)

Satellite Symposium 6
ASCO

Palbociclib as first in class CDK4/6 inhibitor: Milestones since 2015 FDA approval
Date & Time Sep. 1 (Thu), 13:30-14:10 Venue Room D
Chairs
  • Eun Kyung Cho (Gachon University Gil Medical Center, Korea)
Presentation
Detail
  1. Overall survival with Palbociclib: First in class CDK4/6 inhibitor in HR+ HER2- mBC
    Hee Kyung Ahn (Gachon University Gil Medical Center, Korea)

KSSO/KSMO Joint Symposium 2

Current issue & critical tip in MDT trial
Date & Time Sep. 1 (Thu), 14:30-15:30 Venue Room A
Chairs
  • Myung Ah Lee (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
  • Yoo Shin Choi (Chung-Ang University Hospital, Korea)
Presentation
Detail
  1. 1-2.Ongoing adjuvant trial for resectable biliary tract cancers in Korea: KCSG HB20-14
    Joon Oh Park (Samsung Medical Center, Korea)
    Joon Seong Park (Gangnam Severance Hospital, Korea)
  2. Discussion: Q&A
  3. 3-4.Neoadjuvant trial of resectable colorectal cancer
    Soo Yeun Park (Kyungpook National University Hospital, Korea)
    Sang Hee Cho (Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Korea)
  4. Discussion: Q&A

Multidisciplinary Oncology Team Education Session 1 Korean

Cancer associated complication management
Date & Time Sep. 1 (Thu), 14:30-15:30 Venue Room B
Chairs
  • Jae Ho Byun (The Catholic University of Korea Incheon St. Mary's Hospital, Korea)
  • Seok Yun Kang (Ajou University Hospital, Korea)
Presentation
Detail
  1. 1.Cardiovascular toxicity associated with VEGF-signaling pathway inhibitors
    Yun-Gyoo Lee (Kangbuk Samsung Hospital, Korea)
  2. 2.Cancer associated thrombosis(CAT)/ Venous thromboembolism (VTE)
    Hee Jun Kim (Chung Ang University Hospital, Korea)
  3. 3.Chemotherapy-induced peripheral neuropathy (CIPN)
    Sung Hee Lim (Soonchunhyang University Bucheon Hospital, Korea)
  4. 4.Depression in cancer patients
    Hye Yoon Park (Seoul National University Hospital, Korea)

Oncology Multi-Disciplinary Symposium 1 Korean

How to interpret BRCAs and beyond BRCAs gene mutations and how to manage cancer patients with those mutations
Date & Time Sep. 1 (Thu), 14:30-15:30 Venue Room C
Chair
  • In Hae Park (Korea University Guro Hospital, Korea)
Presentation
Detail
  1. 1.CASE Ⅰ: Utilization of up-to-date disease-gene relationship information in genetic counselling
    Young-gon Kim (Samsung Medical Center, Korea)
  2. Panel Discussion
  3. Young-gon Kim (Samsung Medical Center, Korea)
    Kyung-Hun Lee (Seoul National University Hospital, Korea)
    Sook-hee Hong (The Catholic University of Korea. Seoul St. Mary’s Hospital, Korea)
    Kyoung Eun Lee (Ewha Womans University Mokdong Hospital, Korea)
    Sungyoung Lee (Seoul National University Hospital)

  4. 2.CASE Ⅱ: HRD testing in various cancers
    Kyung-Hun Lee (Seoul National University Hospital, Korea)
  5. Panel Discussion
  6. Young-gon Kim (Samsung Medical Center, Korea)
    Kyung-Hun Lee (Seoul National University Hospital, Korea)
    Sook-hee Hong (The Catholic University of Korea. Seoul St. Mary’s Hospital, Korea)
    Kyoung Eun Lee (Ewha Womans University Mokdong Hospital, Korea)
    Sungyoung Lee (Seoul National University Hospital)

Oral Discussion 1

Date & Time Sep. 1 (Thu), 14:30-15:30 Venue Room D
Chairs
  • Sang Cheol Lee (Soonchunhyang University Hospital Cheonan, Korea)
  • Jin Won Kim (Seoul National University Bundang Hospital, Korea)
Presentation
Detail
  1. 1.Preliminary results from the KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS): KCSG AL-20-05
    Tae-Yong Kim (Seoul National University Hospital, Korea)
  2. 2.The first report of K-Umbrella gastric cancer study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of Advanced Gastric Cancer (AGC)
    Sun Young Rha (Yonsei Cancer Center, Yonsei University, Korea)
  3. 3.Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea
    Beung-Chul Ahn (Yonsei University College of Medicine, Korea)
  4. 4.Pilot study examining the feasibility and safety of exercise intervention during palliative chemotherapy in patients with advanced gastrointestinal cancer
    In Gyu Hwang (Chung-Ang University College of Medicine, Korea)
  5. 5.Cancer-specific molecular subtypes from integrative omics profiling show clinical relevance with potential therapeutic opportunities in resectable pancreatic cancer.
    Sang A Park (Cha Bundang Medical Center, Korea)
  6. 6.Diagnosing pancreatic cancer via noncoding RNA liquid biopsy
    Daniel Kim (UC Santa Cruz/Canary Center at Stanford for Cancer Early Detection, USA)

Scientific Symposium 5

New horizons of clinical immuno-oncology in early-stage cancer
As we’ve witnessed unprecedented therapeutic success with immune-checkpoint inhibitors (ICIs) in advanced and/or metastatic cancers, it’s time to move on to the next chapter ultimately to improve the chance of cure in patients with early-stage cancer. In this session, accordingly, current promises and pitfalls of neoadjuvant or adjuvant ICIs treatment will be insightfully discussed with a comprehensive review of biomarkers issues in early-stage cancer. Interestingly, clinical application and experience of intratumoral immunotherapy will also be shared in the session.
Date & Time Sep. 1 (Thu), 15:50-17:20 Venue Room A
Chairs
  • Jin Hyoung Kang (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
  • Young Kwang Chae (Northwestern University, USA)
Presentation
Detail
  1. 1.Promise and pitfalls of immune checkpoint inhibitors for early-stage cancers
    Dae Ho Lee (Asan Medical Center, Korea)
  2. 2.State-of-art immunotherapy in early-stage NSCLC: Adjuvant vs. Neoadjuvant?
    Sun Min Lim (Yonsei Cancer Center, Korea)
  3. 3.Beyond the immune-checkpoint inhibitors: Can intratumoral immunotherapy be another breakthrough?
    Stephane Champiat (Institute Gustave Roussy, France)
  4. 4.Current and future biomarkers of immuno-oncology in early-stage cancer
    Young Kwang Chae (Northwestern University, USA)

JSMO/KSMO Joint Symposium 3

Pharmacogenomics of targeted therapy and IO in Korea and Japan
Date & Time Sep. 1 (Thu), 15:50-17:20 Venue Room B
Chairs
  • Joon Oh Park (Samsung Medical Center, Korea)
  • Narikazu Boku (IMSUT Hospital, Japan)
Presentation
Detail
  1. 1.Toxicity profile of targeted therapy and ADC in Asian patients
    Hidetoshi Hayashi (Kindai University, Japan)
  2. 2.Pharmacogenomics for immunotherapy and immune-related toxicities
    Sook Ryun Park (Asan Medical Center, Korea)
  3. 3.Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitor
    Eun Kyung Lee (National Cancer Center, Korea)
  4. 4.Pharmacogenomic-guided therapy in colorectal cancer
    Taroh Satoh (Osaka University Hospital, Japan)

Scientific Symposium 6

Clinical genomics
The combination of next-generation sequencing and advanced computational data analysis approaches has revolutionized our understanding of the genomic underpinnings of cancer development and progression. Based on this development, clinical genomics represents a paradigm shifting change to health service delivery and practice across many conditions and life-stages. The increasing relevance of genomics for clinical cancer care also highlights several considerable challenges surrounding their implementation. We set aside time to review clinical genomics programs in progress around the world and discuss what kind of effort is needed to develop a model suitable for our situation.
Date & Time Sep. 1 (Thu), 15:50-17:20 Venue Room C
Chairs
  • Yeon Hee Park (Samsung Medical Center, Korea)
  • Atsushi Ohtsu (National Cancer Center Hospital East, Japan)
Presentation
Detail
  1. 1.Improvement of patient care using cancer genomic profiling: SCRUM/CIRCULATE-Japan experience
    Atsushi Ohtsu (National Cancer Center Hospital East, Japan)
  2. 2.Creating accelerated access to genomics-guided precision medicine through innovative trials
    Emile E Voest (The Netherlands Cancer Institute, The Netherlands)
  3. 3.Sharing experiences in interpreting multi-institutional NGS reports for MTB discussions in the KOSMOS study
    Sejoon Lee (Seoul National University Bundang Hospital, Korea)
  4. 4.Current efforts and challenges in tumor-only sequencing
    Hongseok Yun (Seoul National University Hospital, Korea)

Satellite Symposium 7
ASCO

Integrating novel agents into the treatment paradigm for advanced urothelial carcinoma
Date & Time Sep. 1 (Thu), 15:50-16:30 Venue Room D
Chair
  • Sang Joon Shin (Yonsei Cancer Center, Korea)
Presentation
Detail
  1. Integrating novel agents into the treatment paradigm for la/mUC: current and future perspective
    Yoon Ji Choi (Korea University Anam Hospital, Korea)

Satellite Symposium 8
ASCO

Perspective change for first line treatment strategy in advanced renal cell carcinoma
Date & Time Sep. 1 (Thu), 16:40-17:20 Venue Room D
Chair
  • Se Hoon Park (Samsung Medical Center, Korea)
Presentation
Detail
  1. Clinical Benefits of 1L aRCC patient with two-year follow-up in CheckMate9ER
    Inkeun Park (Asan Medical Center, Korea)

Plenary Lecture 2

AI based precision medicine
Professor Fabrice André is an outstanding breast cancer oncologist, who has long been dedicated to clinical research of breast cancer, especially focusing on molecularly-driven personalized treatment. He currently serves as a Director of Research at Institut Gustave Roussy and Chair of the ESMO Translational Research and Precision Medicine Working Group. His innovative research works such as SAFIR -01 and -02 trials navigated a new treatment paradigm of biomarker-driven personalized treatment. In this plenary lecture, he will elucidate the importance of converging artificial intelligence in the upcoming era of precision medicine to further enhance the accuracy and reproducibility of genomic profiling, interpretation, and drug development.
Date & Time Sep. 1 (Thu), 17:20-18:00 Venue Room A
Chair
  • Jin-Hyuk Choi (Ajou University Hospital, Korea)
Presentation
Detail
  1. 1.AI based precision medicine
    Fabrice André (The Institute Gustave-Roussy, France)

Sep. 2 (Fri)

Oncology Multi-Disciplinary Symposium 2

Things to know for resectable UGI cancer management
Date & Time Sep. 2 (Fri), 08:00-08:40 Venue Room A
Chairs
  • Yeul Hong Kim (Korea University College of Medicine, Korea)
  • Dong-Hoe Koo (Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Korea)
Presentation
Detail
  1. 1.Adjuvant Nivolumab (NIVO) in Resected Esophageal or Gastroesophageal Junction Cancer (EC/GEJC) Following Neoadjuvant Chemoradiotherapy (CRT): 14-Month Follow-Up of CheckMate 577
    Ronan Kelly (The Charles A. Sammons Cancer Center at Baylor University Medical Center, USA)
  2. 2.Pathologic evaluation of gastric cancer after chemotherapy (from PRODIGY study)
    Young Soo Park (Asan Medical Center, Korea)

Satellite Symposium 9
ASCO

Looking beneath the surface of HR+HER2- aBC
Date & Time Sep. 2 (Fri), 8:00-8:40 Venue Room B
Chair
  • Kyung Hae Jung (Asan Medical Center University of Ulsan College of Medicine, Korea)
Presentation
Detail
  1. Looking beneath the surface of HR+HER2- Abc
    Dejan Juric (Massachusetts General Hospital, USA)

Satellite Symposium 10
ASCO

Navigating the maze of cancer therapies with the answers in your hands
Date & Time Sep. 2 (Fri), 8:00-8:40 Venue Room C
Chair
  • Young Joo Min (Ulsan University Hospital, Korea)
Presentation
Detail
  1. 1.Oncology deep dive: The role of chemotherapy in the era of cancer immunotherapy
    Keun-Wook Lee (Seoul National University College of Medicine / Seoul National University Bundang Hospital)
  2. 2.Translating idea to practice and beyond: how should CRC be managed in 2022?
    Han Sang Kim (Yonsei Cancer Center, Korea)

Satellite Symposium 11
ASCO

Antiemetic usage today: Risk-adapted approach
Date & Time Sep. 2 (Fri), 8:00-8:40 Venue Room D
Chairs
  • Seong-Hoon Shin (Kosin University GospelHospital, Korea)
Presentation
Detail
  1. Antiemetic usage today: Risk-adapted approach
    Hyewon Ryu (Chungnam National University Hospital, Korea)

Plenary Lecture 3

Mechanism-based biomarkers for PD-1 blockade in cancer therapy
Professor Suzanne Topalian has long been dedicated to immunotherapy for the treatment of cancer. She has been actively involved in research on adoptive T cell therapy using TILs, as well as elucidating the characteristics of T cells required for cancer treatment. She also noted the mechanism of T cell activation as a target for cancer therapy, and played a leading role in the clinical development of PD-1/PD-L1 pathway modulator. In her plenary lecture, she will talk about mechanism-based biomarkers for PD-L1 blockade in cancer therapy.
Date & Time Sep. 2 (Fri), 09:00-09:40 Venue Room A
Chair
  • Tae Won Kim (Asan Medical Center, Korea)
Presentation
Detail
  1. 1.Mechanism-based biomarkers for PD-1 blockade in cancer therapy
    Suzanne L. Topalian (Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, USA)

ASCO/KSMO Joint Symposium 4

Hereditary cancers: Diagnosis, management, and clinical trials
Date & Time Sep. 2 (Fri), 10:00-11:15 Venue Room A
Chairs
  • Keon Uk Park (Keimyung University Dongsan Hospital, Korea)
  • Everett Vokes (University of Chicago Medicine (American Society of Clinical Oncology), USA)
Presentation
Detail
  1. 1.Management of lynch syndrome – Personalized risk assessment, management, and immune checkpoint inhibitor therapy
    Matthew Yurgelun (Dana-Farber Cancer Institute, USA)
  2. 2.Homologous recombination deficiency (HRD): Concepts and Assays for Clinical Trials
    Seock-Ah Im (Seoul National University Hospital, Korea)
  3. 3.Heritable TP53-related cancer syndrome: Diagnostic and therapeutic implications of screening
    Kara N. Maxwell (University of Pennsylvania School of Medicine, Korea)

KOSRO/KSMO Joint Symposium 5

Advance in radiotherapy and clinical application
Date & Time Sep. 2 (Fri), 10:00-11:30 Venue Room B
Chairs
  • Eui Kyu Chie (Seoul National University College of Medicine)
  • Tatsuya Ohno (Gumma University, Japan)
Presentation
Detail
  1. 1.Integration of SABR/SBRT into metastatic disease: From Oligometastases to Immune checkpoint
    Steven J. Chmura (University of Chicago, USA)
  2. 2.Image guided radiotherapy (IGRT), SNUH experience with MR guidance
    Eui Kyu Chie (Seoul National University College of Medicine)
  3. 3.Proton beam therapy for hepatocellular carcinoma
    Tae Hyun Kim (National Cancer Center, Korea)
  4. 4.Current status of carbon ion radiotherapy in Asia
    Tatsuya Ohno (Gumma University, Japan)

Scientific Symposium 7

Diffuse large B-cell lymphoma
The diffuse large B-cell lymphoma (DLBCL) session of KSMO 2022 is an important session at a time when interest in DLBCL has increased as CAR-T cell therapy (Tisagenlecleucel, Kymriah) received reimbursement for recurrent DLBCL from April 2022 in Korea. The contents of this session include the basic part consisting of lectures on pathological tissue and molecular genetic classification, and the clinical part consisting of CAR-T and bispecific antibody therapy. It is expected that it will be a meaningful time to experience the latest knowledge on DLBCL.
Date & Time Sep. 2 (Fri), 10:00-11:30 Venue Room C
Chairs
  • Tae Min Kim (Seoul National University Hospital, Korea)
  • Michael R. Bishop (University of Chicago Medicine, USA)
Presentation
Detail
  1. 1.The molecular substructure and classification of diffuse large B-cell lymphoma
    Margaret Shipp (Harvard Medical School, USA)
  2. 2.Double hit/triple hit lymphoma and high-grade B cell lymphoma, NOS
    Yoon Kyung Jeon (Seoul National University Hospital, Korea)
  3. 3.Bispecific T-cell engaging antibody therapy for DLBCL
    Tae Min Kim (Seoul National University Hospital, Korea)
  4. 4.CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma
    Michael R. Bishop (University of Chicago Medicine, USA)

Satellite Symposium 12
ASCO

The evolving treatment landscape with IO based combinations in 1L GC and 1L RCC treatment
Date & Time Sep. 2 (Fri), 10:00-10:40 treatment Room D
Chair
  • Woo Kyun Bae (Chonnam National University Hwasun Hospital, Korea)
Presentation
Detail
  1. 1.Recently updated data of OPDIVO+Cx, a new treatment for GC 1L approved over the past decade
    Jin Won Kim (Seoul National University Bundang Hospital, Korea)
  2. 2.A paradigm-changing IO DUO, 1L NIVO+IPI for mRCC: Recent updates of clinical data and real-world experiences
    Ji Hyun Park (Konkuk University Medical Center, Korea)

Satellite Symposium 13
ASCO

Transforming treatment in urothelial cancer with first-line maintenance treatment with Bavencio (Avelumab)
Date & Time Sep. 2 (Fri), 10:50-11:30 Venue Room D
Chair
  • Hyo Jin Lee (Chungnam National University Hospital, Korea)
Presentation
Detail
  1. 1.Transforming treatment in urothelial cancer with first-line maintenance treatment with Bavencio (Avelumab)
    In-Ho Kim (Catholic University Seoul St. Mary Hospital, Korea)

Luncheon Symposium 3

Patient management in real practices after the reimbursement approval of KEYTURUDA in the 1st line mNSCLC treatment
Date & Time Sep. 2 (Fri), 11:30-12:10 Venue Room A,B
Chair
  • Sang-We Kim (Asan Medical Center, Korea)
Presentation
Detail
  1. 1.Zoom in the real practice- Pembrolizumab for mNSCLC patients in the 1st line
    Byoung Chul Cho (Yonsei Cancer Center, Korea)

Luncheon Symposium 4

Overview of biosimilar development and introduction to Samfenet and Onbevzi, the MFDS approved biosimilars for oncology treatment
Date & Time Sep. 2 (Fri), 11:30-12:10 Venue Room C,D
Chairs
  • Sang Cheul Oh (Korea University Guro Hospital, Korea)
Presentation
Detail
  1. 1.Quality-based biosimilar development: Samfenet & Onbevzi
    Hue Kwon (Samsung Bioepis, Korea)
  2. 2.Clinical Perspective of Oncology Biosimilars
    Donghoon Shin (Samsung Bioepis, Korea)

KCSG/KSMO Joint Symposium 6

New trends in clinical trials
Date & Time Sep. 2 (Fri), 12:40-14:10 Venue Room A
Chairs
  • Dae Young Zang (Hallym University Sacred Heart Hospital, Korea)
  • Aaron C. Tan (National Cancer Centre Singapore, Singapore)
Presentation
Detail
  1. 1.Patient centric phase I clinical trials
    Aaron R. Hansen (Princess Alexandra Hospital, Metro South Health, Australia)
  2. 2.Reflecting patient's voice: Importance of patient reported outcomes in clinical trials
    Juhee Cho (Samsung Medical Center, Korea)
  3. 3.Decentralized clinical trials: Basic concepts and experiences
    Aaron C. Tan (National Cancer Centre Singapore, Singapore)
  4. 4.To optimize decentralized clinical trials: Trends and challenges
    Heeyoung Kim (Medidata, Korea)

Special Symposium 1

Incorporating nuclear medicine theranostic approaches for cancer management
Date & Time Sep. 2 (Fri), 12:40-14:00 Venue Room B
Chairs
  • Jin Chul Paeng (Seoul National University Hospital, Korea)
  • David Tai Wai Meng (Singapore NCC, Singapore)
Presentation
Detail
  1. 1.Peptide receptor radionuclide therapy and the treatment of neuroendocrine tumors
    David Tai Wai Meng (Singapore NCC, Singapore)
  2. 2.PSMA PET and radiopharmaceutical therapy in the clinic
    Joo Hyun O (Seoul St. Mary's Hospital, Korea)
  3. 3.Current status of nuclear imaging in oncology; beyond FDG PET
    Yong-il Kim (Asan Medical Center, Korea)

Multidisciplinary Oncology Team Education Session 2Korean

ABCs of precision medicine (For beginners of precision medicine)
Date & Time Sep. 2 (Fri), 12:40-14:00 Venue Room C
Chairs
  • Yoon-La Choi (Samsung Medical Center, Korea)
  • Tae-Yong Kim (Seoul National University Hospital, Korea)
Presentation
Detail
  1. 1.Basic concepts and elements of cancer genomics for the clinicians: For the very beginners of precision medicine
    Sehhoon Park (Samsung Medical Center, Korea)
  2. 2.How to apply cancer genome data to clinical practice and research
    Ji-Won Kim (Seoul National University Bundang Hospital, Korea)
  3. 3.Interpretation of immuno-oncology papers and planning for translational research
    Hyung-Don Kim (Asan Medical Center, Korea)
  4. 4.Things to know to interpret NGS report
    Yoon-La Choi (Samsung Medical Center, Korea)

Satellite Symposium 14
ASCO

1L treatment for ALK+NSCLC: How do we decide?
Date & Time Sep. 2 (Fri), 12:40-13:20 Venue Room D
Chair
  • Jin Seok Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. 1L treatment for ALK+NSCLC: How do we decide?
    Te-Chun Hsia (China Medical University Hospital, Taiwan)

Satellite Symposium 15
ASCO

Strategic approach for early stage EGFRm NSCLC patient
Date & Time Sep. 2 (Fri), 13:20-14:00 Venue Room D
Chairs
  • Ki Hyeong LEE (Chungbuk National University Hospital, Korea)
Presentation
Detail
  1. Strategic approach for early stage EGFRm NSCLC patient
    Min Hee Hong (Yonsei Cancer Center, Korea)

Plenary Lecture 4

Exploiting the DNA damage response pathway in cancer therapy
Alan Ashworth, PhD, is President of the UCSF Helen Diller Family Comprehensive Cancer Center, and Sr. Vice President for Cancer Services with UCSF Health. He served as Chief Executive of the Institute of Cancer Research (ICR) and Director of the Breakthrough Breast Cancer Research Centre in London, United Kingdom before joining the UCSF. As a translational biologist and laboratory researcher, he focuses on understanding breast cancer genetics to improve the treatment and care of patients. One of his major contributions was the identification of BRCA2 breast cancer susceptibility gene that is linked to an increased risk for some types of cancer. After that, he opened a new field of treatment by applying PARP inhibitors that induce cell apoptosis by inhibiting the damaged DNA repair mechanisms in tumors with BRCA1- or 2-mutations. In this meeting, he will deliver a lecture about ‘Harnessing DNA repair defects for cancer therapy’.
Date & Time Sep. 2 (Fri), 14:20-15:00 Venue Room A
Chair
  • Seock-Ah Im (Seoul National University Hospital, Korea)
Presentation
Detail
  1. 1.Exploiting the DNA damage response pathway in cancer therapy
    Alan Ashworth (University of California San Francisco, USA)

KSP/KSMO Joint Symposium 7

Digital pathology & AI
Date & Time Sep. 2 (Fri), 15:00-16:30 Venue Room A
Chairs
  • Kee-Taek Jang (Samsung Medical Center, Korea)
  • Faisal Mahmood (Harvard Medical School, USA)
Presentation
Detail
  1. 1.Data-efficient and multimodal computational pathology
    Faisal Mahmood (Harvard Medical School, USA)
  2. 2.AI in urogenital pathology
    Sun Woo Kim (Deep Bio Inc., Korea)
  3. 3.Will artificial intelligence replace a pathologist?
    Kee-Taek Jang (Samsung Medical Center, Korea)
  4. 4.Moving beyond human capabilities in histopathology
    Geert Litjens (Radboud University Medical Center, The Netherlands)

Scientific Symposium 8

Esophageal squamous cell carcinoma
Esophageal cancer, the sixth leading cause of cancer-related death in men, is one of the most prevalent malignancies with high mortality worldwide. Adenocarcinoma frequently occurs in Western countries, but East Asian countries have the highest incidence of esophageal squamous cell carcinoma (ESCC). In these KSMO multidisciplinary treatments sessions, our four prestigious speakers will discuss the recent advances in current standard treatment modes: surgical updates, radiotherapy advances, and innovations in systemic therapies.
Date & Time Sep. 2 (Fri), 15:00-16:30 Venue Room B
Chairs
  • Sang Hee Cho (Chonnam National University Medical School, Korea)
  • Ken Kato (National Cancer Center Hospital, Japan)
Presentation
Detail
  1. 1.Principles and lessons for surgery in esophageal squamous cell carcinoma
    Chang Hyun Kang (Seoul National University Hospital, Korea)
  2. 2.Recent advances in radiation treatment for non-metastatic esophageal squamous cell carcinoma
    Sung Ho Moon (National Cancer Center, Korea)
  3. 3.Optimal adaptation of immune checkpoint inhibitors in locally advanced esophageal squamous cell carcinoma (ESCC)
    Jong-Mu Sun (Samsung Medical Center, Korea)
  4. 4.New treatment strategies for metastatic esophageal squamous cell carcinoma
    Ken Kato (National Cancer Center Hospital, Japan)

ESMO/KSMO Joint Symposium 8

Recent progress of precision medicine using genomic landscape in cooperation with agnostic approach
Date & Time Sep. 2 (Fri), 15:00-16:30 Venue Room C
Chairs
  • Ho Yeong Lim (Samsung Medical Center, Korea)
  • Solange Peters (European Society for Medical Oncology, Switzerland)
Presentation
Detail
  1. 1.Tumor organoids: Opportunities and challenges to guide precision medicine
    Krisztian Homicsko (Lausanne University Hospital, Switzerland)
  2. 2.Current issues to guide clinical decision-making in precision oncology in Europe
    David Planchard (Gustave Roussy, France)
  3. 3.Approach to risk-share for biomarker-driven treatment of rare subgroups of cancer patients
    Jean-Yves Blay (Léon Bérard Center, France)
  4. 4.Accelerating patient access to molecular profiling guided therapy based on genomic alterations in advanced solid tumors in Korea (KOSMOS project)
    Jee Hyun Kim (Seoul National University Bundang Hospital, Korea)

Scientific Symposium 9

Clinical development of radioligand therapy (RLT)
Radioligand therapy (RLT) is a novel therapeutic modality defined by the delivery of radioactive atoms to tumor-associated targets. The development of RLT is a multidisciplinary endeavor and the current clinical application includes neuroendocrine tumor and prostate cancer, but it is expected to be broader in the near future. This session will cover topics including the advent and introduction of RLT, clinical data in neuroendocrine tumor and prostate cancer, and future perspectives of RLT.
Date & Time Sep. 2 (Fri), 15:00-16:15 Venue Room D
Chairs
  • Keon Wook Kang (Seoul National University Hospital, Korea)
  • Jae Lyun Lee (Asan Medical Center, University of Ulsan College of Medicine, Korea)
Presentation
Detail
  1. 1.Overview of radioligand therapy: How radioligand therapy revolutionizes cancer treatment
    Hongyoon Choi (Seoul National University Hospital, Korea)
  2. 2.Advanced PSMA targeting therapy in prostate cancer
    Karim Fizazi (Gustave Roussy, France)
  3. 3.Radioligand therapies in development and future perspectives
    Stephen Moran (Novartis, Switzerland)

KSR/KSMO Joint Symposium 9

Machine learning tech in diagnostic radiology
Date & Time Sep. 2 (Fri), 16:40-17:40 Venue Room A
Chairs
  • Tae Min Kim (Seoul National University Hospital, Korea)
  • Jin-Young Choi (Severance Hospital, Korea)
Presentation
Detail
  1. 1.Experience on radiogenomic study with breast MRI focusing on tumor heterogeneity
    Won Hwa Kim (Kyungpook National University Chilgok Hospital)
  2. 2.Brain tumor
    Ho Sung Kim (Asan Medical Center, Korea)
  3. 3.Radiomics approaches in abdominal cancer
    Jaeseung Shin (Samsung Medical Center, Korea)

Multidisciplinary Oncology Team Education Session 3 Korean

Familial cancer- Diagnosis, education, care
Date & Time Sep. 2 (Fri), 16:40-17:40 Venue Room B
Chairs
  • Soohyeon Lee (Korea University Anam Hospital, Korea)
  • Myong Cheol Lim (National Cancer Center, Korea)
Presentation
Detail
  1. 1.Hereditary breast cancer: Diagnosis and Breast cancer risk management
    Sang Ah Han (Kyung Hee University Hospital at Gangdong, Korea)
  2. 2.Hereditary ovarian cancer: Prevention and therapeutic Implications
    Myong Cheol Lim (National Cancer Center, Korea)
  3. 3.Hereditary colorectal cancer syndromes & Lynch syndrome: Diagnosis, cancer screening and preventive measures
    Jin Young Kim (Keimyung University, Korea)
  4. 4.Genetic testing and counselling of individuals at risk of hereditary cancer syndromes
    Sun-Young Kong (National Cancer Center, Korea)

Oral Discussion 2

Date & Time Sep. 2 (Fri), 16:40-17:40 Venue Room C
Chairs
  • Jae Hong Seo (Korea University College of Medicine, Korea)
  • Sae-Won Han (Seoul National University Hospital, Korea)
Presentation
Detail
  1. 1.Oxaliplatin (3 months versus 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07
    Young Suk Park (Sungkyunkwan University Samsung Medical Center, Korea)
  2. 2.Trastuzumab plus FOLFOX for Gemcitabine/Cisplatin refractory HER2-positive biliary tract cancer: a multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14)
    Choong-Kun Lee (Yonsei Cancer Center, Yonsei University College of Medicine, Korea)
  3. 3.The effect of inpatient palliative care consultation on aggressiveness of antibiotic use at the end of life among patients with terminal cancer
    Shin Hye Yoo (Seoul National University Hospital, Korea)
  4. 4.Efficient and noninvasive T cell therapy platform using autologous peripheral blood PD-1+CD8+ T cells instead of tumor-infiltrating lymphocytes in solid tumors: Ex vivo efficacy
    Yong Wha Moon (Cha Bundang Medical Center, Korea)
  5. 5.Enhancing immunotherapy response by targeting epigenetic modifiers
    Jason Lee (QIMR Berghofer Medical Research Institute, Australia)
  6. 6.CDK9 serves as the potent therapeutic target in tamoxifen resistant breast cancer cells
    Eunji Lo (Sungkyunkwan University School of Medicine, Korea)

Satellite Symposium 16
ASCO

Enabling precision medicine with comprehensive genomic profiling
Date & Time Sep. 2 (Fri), 16:40-17:20 Venue Room D
Chair
  • Tae-You Kim (Seoul National University Hospital, Korea)
Presentation
Detail
  1. 1.Precision medicine in oncology – Today and the future
    Damon Hostin (Illumina, USA)
  2. 2.The basecamp of cancer precision medicine: Comprehensive genomic profiling
    Yeul Hong Kim (Korea University College of Medicine, Korea)